Universal Vision Biotechnology (3218 TT): Steady Revenue and Net Profit Growth in 2022;
394 Views31 Mar 2023 19:11
SUMMARY
- Universal Vision Biotechnology (3218 TT) reported continued growth in 2022, with revenue, operating profit, and net profit increasing 33%, 41%, and 43%, YoY, respectively.
- Revenue from high-margin technical service grew 45% YoY, driven by increasing number of refractive and cataract surgeries performed in Taiwan.
- UVB remains on a steady growth path and started 2023 on a strong note. During the first two months of 2023, the company recorded revenue of NT$661M, up 18% YoY.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
- Universal Vision Biotechnology (3218 TT): Steady Growth Continued in 1H23 Riding on Strong Demand12 Oct 2023
- Universal Vision Biotechnology (3218 TT): Steady Revenue and Net Profit Growth in 2022;31 Mar 2023
- Universal Vision Biotechnology (3218 TT): Not Suffering from Myopia; Clear Long-Term Growth Prospect05 Jan 2023
- Universal Vision Biotechnology (3218 TT): 2021 Revenue Growth of 28% Is Outlier Amid COVID-19 Crisis04 Feb 2022
x